Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2009
08/05/2009CN100522150C Angiogenesis inhibitor
08/04/2009US7569724 Antiproliferative agnets; anticancer agents; skin disorders
08/04/2009US7569698 Process for the isolation and purification of epothilones
08/04/2009US7569696 Process for producing crystal
08/04/2009US7569688 Propane-1, 3-dione derivative
08/04/2009US7569663 Genetically engineered fusion proteins for use in diagnosis and treatment of cancer, viral infections, autoimmune and alloimmune diseases
08/04/2009US7569577 (2S)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol; antiproliferative agents; for treatment of cancers mediated by erbB receptor EGFR tyrosine kinases; psoriasis
08/04/2009US7569571 Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases
08/04/2009US7569570 N-{4-[1-(2,6-difluorobenzyl)-3-(4-fluorophenyl)-5-({methy[2-(2-oxo-1-piperidinyl)ethyl]amino}methyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-N'-ethylurea; antagonistic action for gonadotropin-releasing hormone
08/04/2009US7569569 Pyrrolo[2,3-d]pyrimidine compounds
08/04/2009US7569568 1-[5-(5-tert-Butyl-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; inflammation, chronic inflammatory disease
08/04/2009US7569567 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use
08/04/2009US7569566 Inhibitors of tyrosine kinases
08/04/2009US7569564 Such as 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-yl)-thiophene-2-carbonitrile; estrogen receptor agonists, progesterone receptor antagonists; hormone replacement therapy
08/04/2009US7569561 For treating carcinoma chosen from cervical, breast, colon, head and neck, lung, pancreas, prostate, sarcomas, leukaemias, lymphomas, melanomas and gliomas
08/04/2009US7569538 Vaccines against cancer of the upper respiratory tract or anogenital carcinomas, such as cervical cancer, using fragments of the cyclin-dependent kinase inhibitor P16 protein
08/04/2009US7569387 Specifically binds an MK61 polypeptide produced by immunizing an animal
08/04/2009US7569383 Chimeric flavivirus vectors
08/04/2009US7569351 P53 dependent apoptosis-associated gene and protein
08/04/2009US7569234 Aqueous organic solvent extract of trigonellae, astragali, glehniae and asparagi
08/04/2009CA2523987C Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
08/04/2009CA2496476C Therapeutic use
08/04/2009CA2433785C Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
08/04/2009CA2365281C Human antibodies that bind human il-12 and methods for producing
08/04/2009CA2194673C A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
07/2009
07/30/2009WO2009094634A1 Lytic domain fusion constructs and methods of making and using same
07/30/2009WO2009094427A1 4-pyridinone compounds and their use for cancer
07/30/2009WO2009094426A1 13,13-dimethyl-des-c,d analogs of 1alpha, 25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof
07/30/2009WO2009094417A1 4-pyridinone compounds and their use for cancer
07/30/2009WO2009094360A1 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
07/30/2009WO2009094224A1 Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
07/30/2009WO2009094123A1 Protein kinase inhibitors and use thereof
07/30/2009WO2009093981A1 Triazine compounds as kinase inhibitors
07/30/2009WO2009093972A1 Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026
07/30/2009WO2009093471A1 Apoptosis inhibitor
07/30/2009WO2009093447A1 Anti-tumor agent for gastrointestinal cancer
07/30/2009WO2009093384A1 Polynucleotide or analogue thereof, and gene expression regulation method using the polynucleotide or the analogue thereof
07/30/2009WO2009093253A2 Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression
07/30/2009WO2009093250A2 Targeting of innate immune response to tumor site
07/30/2009WO2009093049A1 Fused pyridines active as inhibitors of c-met
07/30/2009WO2009093032A1 Phthalazinone derivatives
07/30/2009WO2009093013A1 Fused thiophene derivatives as mek inhibitors
07/30/2009WO2009093012A1 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity
07/30/2009WO2009093009A1 Fused tricyclic thiophene derivatives as mek inhibitors
07/30/2009WO2009092892A2 Novel composition for treating the side effects of anticancer treatments
07/30/2009WO2009092891A2 Modification of intrinsically disordered sequences for preparing vaccines
07/30/2009WO2009092796A1 Synephrine derivatives for the treatment of cancer
07/30/2009WO2009092612A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver
07/30/2009WO2009092581A1 Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
07/30/2009WO2009092431A1 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives
07/30/2009WO2009092323A1 Uses of pdcd5 polypeptide for tumor chemotherapy and organ protection
07/30/2009WO2009092295A1 A set of geldanamycin derivatives and their preparation methods
07/30/2009WO2009092278A1 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
07/30/2009WO2009076170A3 Combinations of therapeutic agents for treating cancer
07/30/2009WO2009071892A3 Method for the detection of dead and dying cells
07/30/2009WO2009067243A3 Modulation of cd40 expression
07/30/2009WO2009064854A3 Humanized antibodies against tl1a
07/30/2009WO2009053737A3 Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
07/30/2009WO2009050730A3 Rnai mediated knockdown of numa for cancer therapy
07/30/2009WO2009050228A3 Csf-1r inhibitors for treatment of cancer and bone diseases
07/30/2009WO2009047505A3 Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
07/30/2009WO2009047298A3 Dimers of harmol or of its derivatives and uses thereof
07/30/2009WO2009043464A3 Astressin and beta- endorphin for use as therapeutic agents
07/30/2009WO2009043451A3 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent
07/30/2009WO2009043450A3 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
07/30/2009WO2009043449A3 Use of a peptide as a therapeutic agent
07/30/2009WO2009043447A3 Use of a peptide as a therapeutic agent
07/30/2009WO2009040004A3 Use of a peptide as a therapeutic agent
07/30/2009WO2009033813A3 Use of a peptide as a therapeutic agent
07/30/2009WO2009033774A3 Use of a laminin nonapeptide as a therapeutic agent
07/30/2009WO2009033722A8 Use of a octreotide as a therapeutic agent
07/30/2009WO2009024771A3 Materials and methods for treating cancers which express folate receptors
07/30/2009WO2009013310A3 Process for preparing 7-alpha-[9-(4,4,5,5,5-pentafluorothiopentyl)nonyl]estra-1,3,5(10)-triene-3,17-beta-diol
07/30/2009WO2009006404A3 Heterocyclic compounds useful as raf kinase inhibitors
07/30/2009WO2009002807A3 Indolyl pyrrolidines for the treatment of cancer
07/30/2009WO2008145754A3 Ligands of hvem for treating hematologic malignancies and autoimmune diseases
07/30/2009WO2008145013A8 Fusion protein comprising targeting peptide of cd13 and lidamycin
07/30/2009WO2008141523A8 A strain capable of producing arginine deiminase and the use thereof
07/30/2009WO2008134265A3 Iminosugar for treatment of tumors
07/30/2009WO2008109352A8 Nucleic acid compounds for inhibiting akt gene expression and uses thereof
07/30/2009WO2007112753A8 Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
07/30/2009WO2007088460A8 Tgf-beta modulators and use thereof
07/30/2009US20090192293 Antibodies to non-functional p2x7 receptor
07/30/2009US20090192292 Murine zcytor17 ligand polypeptides and polynucleotides
07/30/2009US20090192226 Materials and Methods for Treatment of Pathological Ocular Vascular Proliferation
07/30/2009US20090192220 Treatment for solid tumors
07/30/2009US20090192215 Cytotoxin Compounds and Methods of Isolation
07/30/2009US20090192214 Drug delivery from rapid gelling polymer composition
07/30/2009US20090192211 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
07/30/2009US20090192198 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
07/30/2009US20090192193 Diagnostic agent and method for detection of cancer and a means for treatment of same
07/30/2009US20090192182 Compound having acidic group which may be protected, and use thereof
07/30/2009US20090192179 Chroman derivatives
07/30/2009US20090192176 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
07/30/2009US20090192169 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
07/30/2009US20090192158 Methods for Treating or Preventing Neoplasias
07/30/2009US20090192156 Phthalazinone derivatives
07/30/2009US20090192149 Imidazo Compounds
07/30/2009US20090192140 Iap bir domain binding compounds
07/30/2009US20090192138 compounds
1 ... 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 ... 2211